Seattle Genetics drug gets OK for additional cancer therapies in Europe

Seattle Genetics’s treatment for high-risk Hodgkin lymphoma patients can now be marketed in Europe. Seattle Genetics (Nasdaq: SGEN) says its global distribution partner Takeda Pharmaceutical Co. has received permission from the European Commission to market Adcetris in 28 EU member countries and Norway, Liechtenstein and Iceland. Adcetris is already commercially available in more than 60 countries around the world, including throughout the EU for two other uses — relapsed Hodgkin lymphoma and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
In conclusion, these results provide new data validating HDACis and, especially, panobinostat as a novel anti-cancer therapy for veterinary applications, while contributing to comparative oncology. PMID: 29983882 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionsOur study supports evidence of an increased risk for diabetes in survivors of childhood cancer. Future research is warranted for better identification of treatment-related risk factors for diabetes in this population.RésuméObjectifsGrâce à l'amélioration constante de la survie après un cancer chez l'enfant, les conséquences à long terme des traitements contre le cancer sur la santé retiennent de plus en plus l'attention. Le diabète apparaît comme une conséquence tardive potentielle de la thérapie contre le cancer. Toutefois,...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
ConclusionsOur study supports evidence of an increased risk for diabetes in survivors of childhood cancer. Future research is warranted for better identification of treatment-related risk factors for diabetes in this population.RésuméObjectifsGrâce à l'amélioration constante de la survie après un cancer chez l'enfant, les conséquences à long terme des traitements contre le cancer sur la santé retiennent de plus en plus l'attention. Le diabète apparaît comme une conséquence tardive potentielle de la thérapie contre le cancer. Toutefois,...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
SummaryThe recent approval of anaplastic lymphoma kinase (ALK) inhibitors for the treatment ofALK-rearranged non-small cell lung cancer (NSCLC) has dramatically transformed cancer therapy. However, leptomeningeal metastases (LM) are frequent and often devastating complications ofALK-rearranged NSCLC, and treatment against LM remains challenging. Herein we report a case of a 19-year-old male diagnosed withALK-rearranged NSCLC with LM. He experienced heavy treatment before introduction of alectinib therapy, which continued for approximately 5.5  years with marked efficacy. However, he experienced recurrence of a bulbar ...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
In this study, we selected a novel CD19 aptamer (LC1) that was a 59-nucleotide single strand DNA. The aptamer could bind to recombinant CD19 protein with a Kd of 85.4 nM, and had minimal cross reactivity to bovine serum albumin (BSA) or ovalbumin (OVA). Moreover, the aptamer was found capable of binding with the CD19-positive lymphoma cells (Ramos and Raji), but not the CD19-negative cell lines (Jurkat and NB4). An aptamer-doxorubicin complex (Apt-Dox) was also formulated, and selectively delivered doxorubicin to CD19-positive lymphoma cells in vitro. The results indicate that aptamer LC1 can recognize CD19-positive tumor ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusion: The multiplex magneto-nanosensor assays enable longitudinal proteomic studies on mouse tumor models to understand tumor development and therapy mechanisms more precisely within a single biological object.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
CONCLUSIONS: Elatol's identification as an eIF4A1 inhibitor with in vivo anti-tumor activities provides proof-of-principle for target-based screening against this highly promising target for cancer therapy. PMID: 29844128 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Health Management | Liechtenstein Health | Lymphoma | Pharmaceuticals